This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saiman, L.
Right arrow Articles by Knirsch, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saiman, L.
Right arrow Articles by Knirsch, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2002, p. 1105-1107, Vol. 46, No. 4
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.4.1105-1107.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Synergistic Activities of Macrolide Antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis

Lisa Saiman,1* Yunhua Chen,1 Pablo San Gabriel,1 and Charles Knirsch2

Department of Pediatrics, Columbia University,1 Pfizer Pharmaceuticals, Inc., New York, New York2

Received 23 August 2001/ Returned for modification 23 October 2001/ Accepted 20 December 2001

Azithromycin and clarithromycin were paired with other antibiotics to test synergistic activity against 300 multidrug-resistant pathogens isolated from cystic fibrosis (CF) patients. Clarithromycin-tobramycin was most active against Pseudomonas aeruginosa and inhibited 58% of strains. Azithromycin-trimethoprim-sulfamethoxazole, azithromycin-ceftazidime, and azithromycin-doxycycline or azithromycin-trimethoprim-sulfamethoxazole inhibited 40, 20, and 22% of Stenotrophomonas maltophilia, Burkholderia cepacia complex, and Achromobacter (Alcaligenes) xylosoxidans strains, respectively.

* Corresponding author. Mailing address: Columbia University, 650 West 168th St., PH 4 West, Rm. 4-470, New York, NY 10032. Phone: (212) 305-9446. Fax: (212) 305-9491. E-mail: LS5{at}columbia.edu.

Antimicrobial Agents and Chemotherapy, April 2002, p. 1105-1107, Vol. 46, No. 4
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.4.1105-1107.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • MacLeod, D. L., Barker, L. M., Sutherland, J. L., Moss, S. C., Gurgel, J. L., Kenney, T. F., Burns, J. L., Baker, W. R. (2009). Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 64: 829-836 [Abstract] [Full Text]  
  • Moskowitz, S. M., Foster, J. M., Emerson, J. C., Gibson, R. L., Burns, J. L. (2005). Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother 56: 879-886 [Abstract] [Full Text]  
  • Hill, D., Rose, B., Pajkos, A., Robinson, M., Bye, P., Bell, S., Elkins, M., Thompson, B., MacLeod, C., Aaron, S. D., Harbour, C. (2005). Antibiotic Susceptibilities of Pseudomonas aeruginosa Isolates Derived from Patients with Cystic Fibrosis under Aerobic, Anaerobic, and Biofilm Conditions. J. Clin. Microbiol. 43: 5085-5090 [Abstract] [Full Text]  
  • Bell, S C, Senini, S L, McCormack, J G (2005). Macrolides in cystic fibrosis. Chronic Respiratory Disease 2: 85-98 [Abstract]  
  • Cai, G., Zhu, S., Yang, S., Zhao, G., Jiang, W. (2004). Cloning, Overexpression, and Characterization of a Novel Thermostable Penicillin G Acylase from Achromobacter xylosoxidans: Probing the Molecular Basis for Its High Thermostability. Appl. Environ. Microbiol. 70: 2764-2770 [Abstract] [Full Text]  
  • San Gabriel, P., Zhou, J., Tabibi, S., Chen, Y., Trauzzi, M., Saiman, L. (2004). Antimicrobial Susceptibility and Synergy Studies of Stenotrophomonas maltophilia Isolates from Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 48: 168-171 [Abstract] [Full Text]  
  • Saiman, L., Marshall, B. C., Mayer-Hamblett, N., Burns, J. L., Quittner, A. L., Cibene, D. A., Coquillette, S., Fieberg, A. Y., Accurso, F. J., Campbell, P. W. III (2003). Azithromycin in Patients With Cystic Fibrosis Chronically Infected With Pseudomonas aeruginosa: A Randomized Controlled Trial. JAMA 290: 1749-1756 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»